A study led by researchers from NYU Grossman School of Medicine and UC San Diego Moores Cancer Center linked the extent of genomic loss of region 9p24 on chromosome 9 in the cancer cells of patients with HPV-negative head and neck squamous cell carcinoma to survival duration after checkpoint inhibitor therapy.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
